Posted by Michael Wonder on 28 May 2021
FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy
28 May 2021 - Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumours have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
This is the first approved targeted therapy for tumours with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers.
KRAS G12C mutations represent about 13% of mutations in non-small cell lung cancers.
